Products
Latest News
FAQ
Log in
|
Search
Search
Filters
Clear All
Study Phase
Early Phase 1
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
Phase 4
Not Applicable
Recruitment Status
Recruiting
Not yet recruiting
Active, not recruiting
Completed
Suspended
Terminated
Withdrawn
Study Type
Interventional
Observational
Expanded Access
Others
Eligibility Sex
All
Female
Male
Healthy Volunteers
All
Include
Exclude
Found
1
clinical trials
|
View Analysis
Sort by:
Newest First
IV Iron and SGLT2 Inhibitor on Ventricular Function and Myocardial Iron Content in Heart Failure With Iron Deficiency
Phase 3
Not yet recruiting
Conditions
Heart Failure, Systolic
Iron Deficiencies
Interventions
Drug: Placebo of Iron Carboxymaltose
Drug: Iron Carboxymaltose
Drug: Placebo of Dapagliflozin
Drug: Dapagliflozin 10mg Tab
Subscribe
First Posted Date
2024-05-30
Last Posted Date
2024-06-03
Lead Sponsor
Hospital de Clinicas de Porto Alegre
Target Recruit Count
99
Registration Number
NCT06434025
Locations
🇧🇷
Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil
Subscribe
Prev
1
Next
© Copyright 2025. All Rights Reserved by MedPath
Home
Terms & Conditions
Privacy Policy